<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>IPO</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730785</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730785-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730619</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730619-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell turns to Hong Kong to fund ADC ambitions</title>
      <description>
        <![CDATA[Following its 2022 debut on Shanghai’s STAR Market, Mabwell (Shanghai) Bioscience Co. Ltd. is aiming to raise up to HK$1.44 billion (US$184.78 million) in an IPO on the Hong Kong Stock Exchange to advance its Nectin4-targeting antibody-drug conjugate (ADC) 9MW-2821 (bulumtatug fuvedotin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730578</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730578-mabwell-turns-to-hong-kong-to-fund-adc-ambitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-exterior.webp?t=1632868875" type="image/png" medium="image" fileSize="621948">
        <media:title type="plain">HKEX exterior</media:title>
        <media:description type="plain">Credit: Lewis Tse Pui Lung - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Med-tech financings steady at $8.8B in Q1, despite volume drop</title>
      <description>
        <![CDATA[Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent years. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730573</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730573-med-tech-financings-steady-at-88b-in-q1-despite-volume-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Layered-charts.webp?t=1706913970" type="image/jpeg" medium="image" fileSize="137002">
        <media:title type="plain">Layered  charts </media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell turns to Hong Kong to fund ADC ambitions</title>
      <description>
        <![CDATA[Following its 2022 debut on Shanghai’s STAR Market, Mabwell (Shanghai) Bioscience Co. Ltd. is aiming to raise up to HK$1.44 billion (US$184.78 million) in an IPO on the Hong Kong Stock Exchange to advance its Nectin4-targeting antibody-drug conjugate (ADC) 9MW-2821 (bulumtatug fuvedotin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730409</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730409-mabwell-turns-to-hong-kong-to-fund-adc-ambitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-exterior.webp?t=1632868875" type="image/png" medium="image" fileSize="621948">
        <media:title type="plain">HKEX exterior</media:title>
        <media:description type="plain">Credit: Lewis Tse Pui Lung - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Obesity-focused Kailera goes for US biopharma record with $625M IPO</title>
      <description>
        <![CDATA[Kailera Therapeutics Inc.’s “obesity-first” approach continues to resonate with investors, with the company pricing an upsized IPO, offering 39 million shares at $16 apiece for gross proceeds of $625 million. Full exercise of the underwriters’ option could add another $93.8 million, bringing the total to nearly $719 million, easily topping Sana Biotechnology Inc.’s $675.6 million 2021 IPO and setting a new record for U.S. biopharma IPOs, according to <em>BioWorld</em> data.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730403</guid>
      <pubDate>Fri, 17 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730403-obesity-focused-kailera-goes-for-us-biopharma-record-with-625m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-IPO-with-chart.webp?t=1776456932" type="image/jpeg" medium="image" fileSize="507410">
        <media:title type="plain">Gold IPO with chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Med-tech financings steady at $8.8B in Q1, despite volume drop</title>
      <description>
        <![CDATA[Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent years. The 2026 total exceeds $6.45 billion in Q1 2024 and $4.69 billion in Q1 2023, indicating continued recovery from the weaker funding environment that followed the 2021 peak. While still below the $16.59 billion recorded in Q1 2019 and the pandemic-era highs, the data suggest that financing activity has stabilized at a higher baseline, with 2026 maintaining momentum despite a slight year-over-year pullback.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730396</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730396-med-tech-financings-steady-at-88b-in-q1-despite-volume-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Layered-charts.webp?t=1706913970" type="image/jpeg" medium="image" fileSize="137002">
        <media:title type="plain">Layered  charts </media:title>
      </media:content>
    </item>
    <item>
      <title>IPO market strengthens in Q1 2026 as biopharma financings reach $22.82B</title>
      <description>
        <![CDATA[Total biopharma financings reached $22.82 billion in the first quarter (Q1) 2026, rising about 74% from $13.12 billion in Q1 2025 but declining 31% from $33.16 billion in Q4 2025. The strong start places 2026 well above the subdued levels seen from 2022 through 2025, though is still below the highs of $38.35 billion in Q1 2021 and $47.25 billion in Q1 2024. Overall, the data indicate a meaningful rebound in financing activity to begin 2026, following a more uneven 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730210</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730210-ipo-market-strengthens-in-q1-2026-as-biopharma-financings-reach-2282b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Virtual-IPO-word-with-stock-graph-and-arrow.webp?t=1775768546" type="image/jpeg" medium="image" fileSize="498778">
        <media:title type="plain">Virtual IPO word with stock graph and arrow</media:title>
      </media:content>
    </item>
    <item>
      <title>VC activity drives March med-tech financings to $2.4B</title>
      <description>
        <![CDATA[Total med-tech financings reached $8.54 billion in the first quarter (Q1) of 2026, reflecting a modest pullback from $9.33 billion in the same period of 2025 but remaining well above previous years. The Q1 2026 total exceeds the $6.45 billion recorded in Q1 2024 and $4.69 billion in Q1 2023, signaling continued recovery from the post-2021 downturn.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730138</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730138-vc-activity-drives-march-med-tech-financings-to-24b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-arrows-smartphone.webp?t=1768508815" type="image/jpeg" medium="image" fileSize="432030">
        <media:title type="plain">Hand holding smartphone with dollar sign, arrows hovering</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma financings nearly double vs. 2025 to $25.1B</title>
      <description>
        <![CDATA[Total biopharma financings reached $25.14 billion in the first quarter (Q1) of 2026, nearly doubling the $13.12 billion in the Q1 2025. The early 2026 total comes in above the $13.19 billion recorded in 2023 and $13.66 billion in 2022, though it remains below the $38.27 billion during the same period in 2021 and $47.25 billion in 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730235</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730235-biopharma-financings-nearly-double-vs-2025-to-251b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gray-and-green-glass-dollar-symbols-with-arrow-pointing-up.webp?t=1731016850" type="image/jpeg" medium="image" fileSize="116588">
        <media:title type="plain">Gray and green glass dollar symbols with arrow pointing up</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma financings nearly double vs. 2025 to $25.1B</title>
      <description>
        <![CDATA[Total biopharma financings reached $25.14 billion in the first quarter (Q1) of 2026, nearly doubling the $13.12 billion in the Q1 2025. The early 2026 total comes in above the $13.19 billion recorded in 2023 and $13.66 billion in 2022, though it remains below the $38.27 billion during the same period in 2021 and $47.25 billion in 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730119</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730119-biopharma-financings-nearly-double-vs-2025-to-251b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gray-and-green-glass-dollar-symbols-with-arrow-pointing-up.webp?t=1731016850" type="image/jpeg" medium="image" fileSize="116588">
        <media:title type="plain">Gray and green glass dollar symbols with arrow pointing up</media:title>
      </media:content>
    </item>
    <item>
      <title>Imbiologics crosses $1B market cap with Kosdaq debut </title>
      <description>
        <![CDATA[Imbiologics Corp.’s market capitalization reached ₩1.5 trillion (US$1.02 billion) on its Kosdaq debut March 20, as the biotech seeks to become a leading antibody drugmaker for autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729897</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729897-imbiologics-crosses-1b-market-cap-with-kosdaq-debut</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ha-Gyong-sik-CEO-Imbiologics-3-20.webp?t=1774038809" type="image/jpeg" medium="image" fileSize="550552">
        <media:title type="plain">Ha-Gyong-sik, CEO, Imbiologics</media:title>
        <media:description type="plain">Imbiologics CEO Ha-Gyong-sik at the company's IPO ceremony.</media:description>
      </media:content>
    </item>
    <item>
      <title> Imbiologics crosses $1B market cap with Kosdaq debut </title>
      <description>
        <![CDATA[Imbiologics Corp.’s market capitalization reached ₩1.5 trillion (US$1.02 billion) on its Kosdaq debut March 20, as the biotech seeks to become a leading antibody drugmaker for autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729763</guid>
      <pubDate>Fri, 20 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729763-imbiologics-crosses-1b-market-cap-with-kosdaq-debut</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ha-Gyong-sik-CEO-Imbiologics-3-20.webp?t=1774038809" type="image/jpeg" medium="image" fileSize="550552">
        <media:title type="plain">Ha-Gyong-sik, CEO, Imbiologics</media:title>
        <media:description type="plain">Imbiologics CEO Ha-Gyong-sik at the company's IPO ceremony.</media:description>
      </media:content>
    </item>
    <item>
      <title>Kanaph’s $27M IPO to aid multi-modality cancer, immune portfolio </title>
      <description>
        <![CDATA[Multi-modality platform company Kanaph Therapeutics Inc. raised ₩40 billion (US$26.7 million) through its Kosdaq stock sale March 16, becoming the first Korean biotech to go public this year. The Seoul-based company’s shares (KOSDAQ:0082N0) climbed to ₩70,000 in intraday trading before closing at ₩50,600 – 153% higher than the offering price.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729715</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729715-kanaphs-27m-ipo-to-aid-multi-modality-cancer-immune-portfolio</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Lee-Byoung-chul-CEO-Kanaph-3-16.webp?t=1774018081" type="image/jpeg" medium="image" fileSize="717835">
        <media:title type="plain">Lee Byoung-chul, CEO, Kanaph</media:title>
        <media:description type="plain">Kanaph CEO Lee Byoung-chul at the company's IPO ceremony.</media:description>
      </media:content>
    </item>
    <item>
      <title>Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs </title>
      <description>
        <![CDATA[Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729714</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729714-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Imbiologics-CEO-Ha-Gyong-sik-hero-03-13-26.webp?t=1773432672" type="image/jpeg" medium="image" fileSize="633322">
        <media:title type="plain">Ha Gyong sik giving a presentation</media:title>
        <media:description type="plain">Ha Gyong-sik, CEO, Imbiologics</media:description>
      </media:content>
    </item>
    <item>
      <title>Kanaph’s $27M IPO to aid multi-modality cancer, immune portfolio </title>
      <description>
        <![CDATA[Multi-modality platform company Kanaph Therapeutics Inc. raised ₩40 billion (US$26.7 million) through its Kosdaq stock sale March 16, becoming the first Korean biotech to go public this year. The Seoul-based company’s shares (KOSDAQ:0082N0) climbed to ₩70,000 in intraday trading before closing at ₩50,600 – 153% higher than the offering price.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729533</guid>
      <pubDate>Mon, 16 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729533-kanaphs-27m-ipo-to-aid-multi-modality-cancer-immune-portfolio</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Lee-Byoung-chul-CEO-Kanaph-3-16.webp?t=1774018081" type="image/jpeg" medium="image" fileSize="717835">
        <media:title type="plain">Lee Byoung-chul, CEO, Kanaph</media:title>
        <media:description type="plain">Kanaph CEO Lee Byoung-chul at the company's IPO ceremony.</media:description>
      </media:content>
    </item>
    <item>
      <title>Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs </title>
      <description>
        <![CDATA[Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729495</guid>
      <pubDate>Fri, 13 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729495-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Imbiologics-CEO-Ha-Gyong-sik-hero-03-13-26.webp?t=1773432672" type="image/jpeg" medium="image" fileSize="633322">
        <media:title type="plain">Ha Gyong sik giving a presentation</media:title>
        <media:description type="plain">Ha Gyong-sik, CEO, Imbiologics</media:description>
      </media:content>
    </item>
    <item>
      <title>Med-tech financings open 2026 with record deal volume</title>
      <description>
        <![CDATA[Med-tech financings totaled $6.08 billion in the first two months of 2026, slightly below the $6.31 billion raised in January to February 2025, a year-over-year decline of about 4%. Even so, the early 2026 total remains well above the openings seen in 2020 ($5.61 billion), 2022 ($4.36 billion), 2023 ($1.67 billion) and 2024 ($4.66 billion).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729453</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729453-med-tech-financings-open-2026-with-record-deal-volume</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Coins-and-charts.webp?t=1614799981" type="image/png" medium="image" fileSize="413156">
        <media:title type="plain">Coins and charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma financings jump 81% in early 2026</title>
      <description>
        <![CDATA[Biopharma financings totaled $16.78 billion in the first two months of 2026, about an 81% year-over-year rise from $9.28 billion in January to February 2025. While still below the outsized $33.29 billion recorded in the same period of 2024, and $24.37 billion in 2021, the early 2026 total significantly outpaces the more subdued levels seen in 2022 ($7.48 billion) and 2023 ($7.66 billion).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729357</guid>
      <pubDate>Fri, 06 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729357-biopharma-financings-jump-81-in-early-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-arrow-up.webp?t=1588893169" type="image/png" medium="image" fileSize="187168">
        <media:title type="plain">Dollar arrows pointing upward</media:title>
      </media:content>
    </item>
    <item>
      <title>Minimed IPO raises $560M as it splits from Medtronic</title>
      <description>
        <![CDATA[Pricing shares at $20 each, below the intended price range, insulin delivery company Minimed Group Inc. debuted with an IPO on Nasdaq March 6, raising $560 million. The company offered a total of 28 million shares, which would have brought the Northridge, Calif.-based company $742 million in gross proceeds if the IPO had priced at the midpoint of the $25-to-$28 price range disclosed in February.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729356</guid>
      <pubDate>Fri, 06 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729356-minimed-ipo-raises-560m-as-it-splits-from-medtronic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>TSLP still plays well, Generates $400M IPO </title>
      <description>
        <![CDATA[Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is phase III-stage TSLP-targeting antibody GB-0895 and the company’s assigned Nasdaq ticker is GENB. The offering is expected to close on March 2.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729255</guid>
      <pubDate>Fri, 27 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729255-tslp-still-plays-well-generates-400m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-money.webp?t=1589580854" type="image/png" medium="image" fileSize="658149">
        <media:title type="plain">IPO money</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic’s diabetes unit Minimed seeks $784M in IPO</title>
      <description>
        <![CDATA[Minimed Group Inc., Medtronic plc’s diabetes business, is looking to raise up to $784 million in its IPO. Medronic last May revealed plans to spin off the unit as an independent public company and expected to complete the separation within 18 months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729196</guid>
      <pubDate>Tue, 24 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729196-medtronics-diabetes-unit-minimed-seeks-784m-in-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-coins.webp?t=1588705630" type="image/png" medium="image" fileSize="384858">
        <media:title type="plain">IPO, coins, financial chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies </title>
      <description>
        <![CDATA[Innovacell Inc. launched a ¥14.16 billion (US$91.2 million) stock sale on the Tokyo Stock Exchange Feb. 24, ending a near two-year lull of biotech listings in Japan while signaling a dynamic year ahead for cell-based therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729194</guid>
      <pubDate>Tue, 24 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729194-innovacells-91m-tokyo-ipo-to-fund-incontinence-cell-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Glass-yen-yuan-symbol.webp?t=1664308599" type="image/png" medium="image" fileSize="289038">
        <media:title type="plain">Glass yen/yuan symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>First profit in six years positions Leo Pharma for long-awaited IPO</title>
      <description>
        <![CDATA[After 118 years as a private company, dermatology specialist Leo Pharma A/S is poised to complete an IPO after reporting a full-year net profit for the first time since 2018.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729074</guid>
      <pubDate>Wed, 18 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729074-first-profit-in-six-years-positions-leo-pharma-for-long-awaited-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-exam-with-dermatoscope.webp?t=1717709526" type="image/jpeg" medium="image" fileSize="197750">
        <media:title type="plain">Skin exam with dermatoscope</media:title>
      </media:content>
    </item>
    <item>
      <title>IPO window reopens, med-tech class of 2025 gains 26%</title>
      <description>
        <![CDATA[After a prolonged downturn, the med-tech IPO market rebounded in 2025, with deal value surging to $13.01 billion across 31 offerings. The recovery followed two muted years, with just $619 million raised in 2024 and a low-point of $110 million in 2023.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728851</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728851-ipo-window-reopens-med-tech-class-of-2025-gains-26</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Financing-IPO-up-arrow-stock.webp?t=1588707556" type="image/png" medium="image" fileSize="334505">
        <media:title type="plain">IPO, coins, upward arrow</media:title>
      </media:content>
    </item>
    <item>
      <title>Heart intervention device-maker Insight lands $143M SSE IPO</title>
      <description>
        <![CDATA[Insight Lifetech Co. Ltd. listed on the Shanghai Stock Exchange’s STAR market via an unprofitable biotech track reinstated last year, with the Feb. 5 IPO raising ¥998.64 million (US$143.93 million).]]>
      </description>
      <guid>http://www.bioworld.com/articles/728803</guid>
      <pubDate>Tue, 10 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728803-heart-intervention-device-maker-insight-lands-143m-sse-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Insight-Lifetech-IPO-ceremony-2-6.webp?t=1770412908" type="image/jpeg" medium="image" fileSize="862498">
        <media:title type="plain">Insight Lifetech IPO ceremony</media:title>
        <media:description type="plain">Insight Lifetech bell-ringing ceremony at the Shanghai Stock Exchange Feb. 5, 2026. Credit: Insight Lifetech Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>2026 kicks off with $10.8B January financing haul</title>
      <description>
        <![CDATA[Total biopharma financings rose to $10.79 billion in January 2026, up from $9.08 billion in December. The monthly total nearly matched the January 2024 record of $10.9 billion, far exceeding the $6.82 billion average monthly haul in 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728801</guid>
      <pubDate>Tue, 10 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728801-2026-kicks-off-with-108b-january-financing-haul</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Global investors optimistic about med-tech exits in 2026</title>
      <description>
        <![CDATA[Global investors in med tech are confident about exit opportunities in the year ahead. The strategics have already started making acquisitions, the IPO window – which reopened last year – is expected to remain active, and the investment firms have companies in their portfolios that are well-positioned for exit. With fundamentals in the sector still robust, 2026 is expected to reward companies that deliver clear clinical value.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728698</guid>
      <pubDate>Mon, 09 Feb 2026 12:05:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728698-global-investors-optimistic-about-med-tech-exits-in-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Currency-symbols-on-white-background.webp?t=1770672261" type="image/jpeg" medium="image" fileSize="170319">
        <media:title type="plain">White currency symbols on white background</media:title>
      </media:content>
    </item>
    <item>
      <title>More biopharma IPOs: Agomab raises $200M, Spyglass gets $150M</title>
      <description>
        <![CDATA[Another two biopharma companies priced IPOs on Nasdaq to raise a combined $350 million, becoming the fourth and fifth firms to debut on U.S. markets in 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728763</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728763-more-biopharma-ipos-agomab-raises-200m-spyglass-gets-150m</link>
    </item>
    <item>
      <title>Heart intervention device-maker Insight lands $143M SSE IPO</title>
      <description>
        <![CDATA[Insight Lifetech Co. Ltd. listed on the Shanghai Stock Exchange’s STAR market via an unprofitable biotech track reinstated last year, with the Feb. 5 IPO raising ¥998.64 million (US$143.93 million).]]>
      </description>
      <guid>http://www.bioworld.com/articles/728662</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728662-heart-intervention-device-maker-insight-lands-143m-sse-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Insight-Lifetech-IPO-ceremony-2-6.webp?t=1770412908" type="image/jpeg" medium="image" fileSize="862498">
        <media:title type="plain">Insight Lifetech IPO ceremony</media:title>
        <media:description type="plain">Insight Lifetech bell-ringing ceremony at the Shanghai Stock Exchange Feb. 5, 2026. Credit: Insight Lifetech Co. Ltd.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
